What this means
This trial plans to check whether a new shot is safe and triggers an immune response similar to a current shot. No results have been posted yet, so we do not know how it turned out.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 65 and over
- Where
- 1 site
The science
- Registered title
- Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
- Trial ID
- NCT07883928 ↗
- Phase
- PHASE 2 / PHASE 3
- Study type
- interventional
- Conditions
- Influenza A, Influenza B, Influenza Vaccination
- What is tested
- vaccination of GC3114B, Vaccination of Efluelda
- Sponsor
- GC Biopharma Corp
- Ages
- 65 Years to no maximum
- Dates
- First posted Oct 20, 2026 · updated Oct 20, 2026
Registry summary
This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older. The study will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.
After providing written informed consent, participants will undergo screening to determine whether they are eligible. Eligible participants will be randomly assigned to a study group and receive a single dose of the investigational product on Day 0.
Participants will record solicited adverse events in a subject diary from Day 0 through Day 7. The study site will contact participants by telephone on Day 7 to check on adverse events, concomitant medications, and diary completion. On Day 28, participants will visit the study site for safety follow-up and blood sampling. Participants will be monitored for serious adverse events for 6 months.
Sites (1)
- Korea University Guro Hospital, Seoul, Seoul, South Korea